24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
NCT ID: NCT01686295
Last Updated: 2012-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2012-07-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The System is placed on the head and adjusted to a comfortable size by rotating knobs on the side of the device. If needed, subjects may replace the soft pad on the inside of the device with the thinner pad provided. There will be 2 options for using the product. The subject will either insert the 5-V AC power adapter pin into the device remote control, and the 5-V adapter will then be plugged into the AC outlet; or the subjects will use the rechargeable battery pack and belt clip. The battery pack is an external device which will allow the subject the freedom of mobility while treating the hair. The rechargeable battery pack will hold a charge for up to 3 hours prior to needing to be recharged. The iRestore™ remote control clips into the battery holster and the pack plugs into the remote. The battery pack can be placed in a pocket, clipped to the belt or placed next to the subject. The device will be turned on by pressing the power button on the remote control. The dome of the device is to be moved forward and backward by the subject to brush through the hair and increase the direct light which comes into contact with the scalp. Subjects will then position the dome at the front of the scalp and press the start button to begin a 10-minute session. Note: As a safety feature, the dome must be placed onto the head prior to starting the device. A timer will indicate the completion of the session with a beep sound. Subjects will complete the same process as done with the front of the scalp with the dome repositioned to the middle of the scalp and then the back of the scalp. Once all 3 positions have received the 10 minute treatment, the power button is to be held for approximately 3 seconds to turn the device off. Once off the device is to be unplugged from the wall.
The control device will be identical to the test device except that the laser-emitting units will be disabled. A standard light will be emitted from the device. Subjects and clinical staff engaged in the performance of assessments will be treatment blinded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
iRestore Hair Rejuvenation System
Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
iRestore Hair Rejuvenation System
This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
Sham Device Arm
This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
sham device
This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iRestore Hair Rejuvenation System
This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
sham device
This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Are male or female, 25 to 60 years of age;
2. If male, have Norwood-Hamilton classifications of IIa to V male pattern baldness;
3. If female, have Ludwig Scale classifications I-4, II-1, II-2, or frontal;
4. Are willing to have a tattoo created on the target area;
5. Have been experiencing active hair loss within the last 12 months;
6. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence or partner's vasectomy: abstinence or partner's vasectomy are acceptable if the female agrees to implement one of the other acceptable methods of birth control if her lifestyle or partner changes);
7. Have Fitzpatrick Skin Type I-IV (See Table 1 Below);
8. Are willing to have the target area hair clipped;
9. Read, understand, and sign a photographic release form(s); and
10. Read, understand, and sign an informed consent document after being advised of the nature of the study.
Table 1: Fitzpatrick Skin Types I Always burns easily, never tans II Always burns easily, tans minimally III Burns moderately, tans gradually (light brown) IV Burns minimally, always tans well (moderate brown) V Rarely burns, tans very well (moderate brown) VI Never burn, deeply pigmented
Exclusion Criteria
1. Have used any of the following medications within 6 months prior to enrollment:
* minoxidil, finasteride (or any other 5α-reductase inhibitor medications);
* medications with anti-androgenic properties (eg, cyproterone, spironolactone, ketoconazole, flutamide, and bicalutamide);
* topical estrogens, progesterone, tamoxifen, anabolic steroids;
* medications that can potentially cause hypertrichosis (eg, ciclosporin, diazoxide, phenytoin, and psoralens);
* oral glucocorticoids (inhaled glucocorticoids are permitted);
* lithium or phenothiazines;
* medications of known or suspected phototoxicity (eg, tetracyclines, thiazides, certain NSAIDs);
* other medications which, in the opinion of the investigator, may interfere with the performance of study assessments or place the subject at undue risk;
2. Will not agree to refrain from changing hair color and hair style during the course of the study;
3. Have had a hair transplant, scalp reduction, hair weave, or tattoo which, in the opinion of the investigator, may interfere with the performance of the study assessments;
4. Are using or have used depilatories, razors, or wax on the scalp to an extent which, in the opinion of the investigator, may interfere with the performance of the study assessments;
5. Have psoriasis, active dermatitis/eczema, or severe acne on the scalp area;
6. Have diabetes requiring exogenous insulin;
7. Have cataracts;
8. Have any medical condition which, in the opinion of the investigator, could affect hair growth (eg, Human Immunodeficiency Virus, connective tissue disease, inflammatory bowel disease);
9. Have very little contrast between hair color and scalp, eg, are of a fair hair color (eg, white or very blond) and have very pale skin;
10. Are females who are pregnant, planning to become pregnant during the study, or breastfeeding; and/or
11. Are, in the opinion of the investigative personnel, unable to comprehend and/or otherwise comply with any aspect of study requirements.
25 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TKL Research, Inc.
INDUSTRY
Freedom Laser Therapy, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Dosik, MD
Role: PRINCIPAL_INVESTIGATOR
TKL Research, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TKL Research Inc.
Paramus, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
C Andresen
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS940112
Identifier Type: OTHER
Identifier Source: secondary_id
CS940112
Identifier Type: -
Identifier Source: org_study_id